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CC BY-NC-ND license.Two decades ago, the American streptococcal researcher
Floyd Denny reﬂected on the history of research, manage-
ment, and prevention of rheumatic fever (RF) and rheumatic
heart disease (RHD) since T. Duckett Jones’s pivotal paper
outlining the diagnostic criteria for RF [1,2]. He paraphrased
Milton Markowitz’s description of the years between 1950
and 1980, respectively, as the decade of discovery (when the
most important ﬁndings about methods to prevent RF were
made), the decade of dissemination (during which the
message about these approaches, particularly primary pro-
phylaxis, was widely practiced in the Unites States), and the
decade of dissonance (during which limitations of these
approacheswere noted, but alsowhenRFbegan to disappear
from the United States) [3]. Denny went on to label the
1980s as the decade of dismay, because of the return of RF
and of severe group A streptococcal infections in some re-
gions of the Unites States.
Those labels aptly summarized 40 critical years for RF
and RHD, particularly in the United States. But with the
passing of a further 2 decades plus, it may be appropriate
to take a more global view of RF and RHD. As interest in
RHD waned in wealthy countries between the 1970s and
the 1990s, in parallel with reducing rates of disease in
those same countries, attention of the cardiology commu-
nity turned to the escalating epidemic of ischemic heart
disease, while infectious diseases specialists focused on the
human immunodeﬁciency virus, malaria, tuberculosis, and
the emergence of antibiotic-resistant bacteria.
But it was during this period that the problem of RF
and RHD in developing countries became increasingly
recognized. In 1985, Dr. Alan Bisno stated: “While rheu-
matic fever has become a rare disease in many parts of the
United States. the disease continues to devastate many of
the poorer and most densely populated areas of the globe”
[4]. Although it was not clear if RF had always been a
problem in these countries, just under-recognized, or if in
fact there had been a real increase in the disease in recent
years [5], interest began to shift to RF and RHD in low- and
middle-income countries.
Led by the World Health Organization [WHO], a global
program of RHD control was established in 16 countries and
later expanded to 22 in the mid-1980s [6]. Although under-
funded, this global program had some remarkable achieve-
ments: the concept of register-based control programs was
borne, as was the idea of screening school-aged children for
RHD; the WHO published the ﬁrst global guideline on RHD;
and some pilot programs managed to persist and even later
report dramatic reductions in disease burden [7,8]. But byGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 185-1862000, the WHO global program was abandoned. This
development, combined with the lack of new researchers
emerging from the United States and other afﬂuent countries,
signaled the nadir of global interest in RF/RHD.
But since then, a new era has begun, notable for the
emergence of voices from regions where RF/RHD remains a
major problem. Research, policy, and advocacy are now
dominated by individuals, and some organizations, working
in low- and middle-income countries (particularly in sub-
Saharan Africa, South Asia, the Paciﬁc, and Latin America),
or in wealthy countries where RHD remains prevalent in
subgroups (often indigenous or other populations living in
poverty, such as in Australia and New Zealand). This
remarkable transformation has resulted in increased advocacy
for so-called comprehensive approaches to RF/RHD control,
encompassing primary and secondary prevention, treatment
of established RHD, and broad education and health pro-
motion strategies [9]. It has led to some traditional views being
challenged, including the classic teaching that streptococcal
skin infection has no role in RF pathogenesis [10], molecular
mimicry may not be the basis of disease [11], and even the
Jones criteria have been found to be wanting in places where
RF remains a scourge [12,13]. This “southern shift” has also
seen a new generation of RF/RHD researchers coming from
these countries, many conducting high-end genetic, epide-
miological, clinical, and pathogenesis research.
The new era has also resulted in wonderful collabora-
tions on a global scale. Efforts to develop RF vaccines have
researchers from countries such as the United States,
Australia, andNewZealand collaboratingwith researchers in
Mali, Nicaragua, Fiji, India, and South Africa [14]. A truly
global effort resulted in a pivotal publication of agreed
criteria for the echocardiographic diagnosis of asymptomatic
RHD [15], and an ongoing collaboration to increase uptake
of these guidelines and ensure that protocols for RHD
screening are evidence-based, practical, affordable, and
supported by essential secondary prophylaxis programs.
New organizational leadership had emerged during
this era as well. The gap left by a waning of activity and
interest from WHO has been partly ﬁlled by the World
Heart Federation, which has recently published 5 targets to
achieving control of RF/RHD by 2025 [16]. Organizations
such as NCD Child have also included RHD in their
agendas. As more players come into the ﬁeld, and hope-
fully organizations that have RHD as their major focus, and
if the current sense of collaboration and collegiality con-
tinues to be fostered, then the prospects of real progress in
RF/RHD control are excellent over the coming 2 decades.j.gheart.2013.08.003
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186The new era of RF/RHD was encapsulated at the recent
World Congress on Paediatric Cardiology and Cardiac
Surgery, held in Cape Town in February 2013. This con-
ference had a major focus on RHD, and that agenda was
dominated by participants from low- and middle-income
countries. This issue of Global Heart is dedicated to
RF/RHD and largely arises from presentations made at the
2013 World Congress on Paediatric Cardiology and Car-
diac Surgery.
We still have a longway to go to control RF and RHD. All
indications are that the disease burden ﬁgures commonly
cited (more than 15 million cases and more than 200,000
deaths annually) will be shown to be dramatic underestimates
when the 2010 Global Burden of Disease, Injuries, and Risk
Factors reports its updated data on RHD over the next 12
months. There continue to be no low- or middle-income
countries with coordinated, national control programs. We
still do not have a RF vaccine, although the recent
announcement that the Australian and New Zealand gov-
ernments are jointly sponsoring a program to fast track
development of a RF vaccine gives hope that this may be
achievable.
But we must keep in mind that, although there are still
gaps in our knowledge about understanding the patho-
genesis of RF, the role of skin infections, the relevance of
so-called borderline RHD detected on echocardiography,
and others, the major gap is one of implementation [17].
There is no doubt that, if we put into practice the
knowledge we already have, the majority of deaths from
RHD around the world, as well as the new cases that
continue to occur, could be prevented right now. This
requires implementation science, but it also requires
advocacy, awareness, commitment, coordination, and
resources. At least the new era means that the future of
RF/RHD science and control is in good hands.
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